公开(公告)号：EP0730657A1

公开(公告)日：1996-09-11

申请号：EP95902161.0

申请日：1994-11-22

申请人： RHONE-POULENC RORER S.A. ,  INSTITUT PASTEUR ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

发明人： BEUZARD, Yves ,  DANOS, Olivier ,  DESCAMPS, Vincent ,  HEARD, Jean-Michel ,  MOULLIER, Philippe ,  NAFFAKH, Nadia ,  PERRICAUDET, Michel ,  VAINCHENKER, William

IPC分类号： C12N15 ,  A61K9 ,  A61K35 ,  A61K38 ,  A61K39 ,  A61K48 ,  A61P5 ,  A61P7 ,  A61P13 ,  A61P15 ,  A61P43 ,  C07H21 ,  C07K14 ,  C12N5

CPC分类号： A61K38/1816 ,  A61K48/00 ,  C07K14/505

摘要： The present invention provides cell compositions for in vivo implantation, and designed for the sustained and controlled delivery of therapeutic substances.

公开(公告)号：EP0702723A1

公开(公告)日：1996-03-27

申请号：EP94914431.0

申请日：1994-04-21

申请人： INSTITUT PASTEUR

发明人： MOULLIER, Philippe ,  DANOS, Olivier ,  HEARD, Jean-Michel ,  FERRY, Nicolas

IPC分类号： C12N15 ,  A61K9 ,  A61K31 ,  A61K35 ,  A61K47 ,  A61K48 ,  A61L27 ,  A61P7 ,  A61P31 ,  C07K14 ,  C12N5 ,  C12N9 ,  A61K38 ,  C12R1

CPC分类号： A61K9/0024 ,  A61K35/12 ,  A61K38/00 ,  A61K48/00 ,  A61L27/3604 ,  A61L27/3608 ,  A61L27/3683 ,  A61L27/38 ,  A61L27/3804 ,  A61L27/3839 ,  A61L27/3895 ,  C07K14/505 ,  C07K14/721 ,  C12N5/0068 ,  C12N9/10 ,  C12N9/1051 ,  C12N9/2402 ,  C12N15/86 ,  C12N2510/02 ,  C12N2533/18 ,  C12N2533/30 ,  C12N2533/54 ,  C12N2740/13043 ,  C12N2740/16043 ,  C12Y204/01017 ,  C12Y302/01031 ,  C12Y302/01076

摘要： The invention relates to an implant obtained by assembling in vitro various elements in order to form a neo-organ which is introduced preferably in the peritoneal cavity of the recipient. The implant comprises a biocompatible support intended to the biological anchoring of cells; cells having the capacity of expressing and secreting naturally or after recombination a predetermined compound, for example a compound having a therapeutical interest; and a constituent capable of inducing and/or promoting the geling of said cells. The invention also relates to a kit for the preparation of the implant as well as to a new recombinant retroviral vector comprising a provirus DNA sequence modified in that the genes gag, pol and env have been deleted at least partially so as to obtain a proviral DNA capable of replication. The invention also relates to recombinant cells comprising the new retroviral vector.

公开(公告)号：EP1363662A2

公开(公告)日：2003-11-26

申请号：EP02708352.6

申请日：2002-02-26

申请人： INSTITUT PASTEUR ,  INSTITUT NATIONAL DE LA SANTE ETDE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DELA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： SCHWARTZ, Olivier ,  BUSEYNE, Florence ,  MARSAC, Delphine ,  MICHEL, Marie-Louise ,  RIVIERE, Yves ,  HEARD, Jean-Michel

IPC分类号： A61K39/21 ,  C07K14/15 ,  C07K14/155 ,  C07K14/16 ,  C12N7/04 ,  G01N33/50

CPC分类号： G01N33/567 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/57 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16023 ,  C12N2740/16034 ,  C12N2740/16062 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2760/20222 ,  C12N2760/20234 ,  G01N33/505 ,  G01N33/5082 ,  G01N2333/16

摘要： Dendritic cells and macrophages can process extracellular antigens for presentation by MHC-I molecules. HIV-1 epitopes derived from incoming virions are presented through the exogenous MHC-I pathway in primary human dendritic cells, and to a lower extent in macrophages, leading to cytotoxic T lymphocyte activation in the absence of viral protein neosynthesis. Exogenous antigen presentation required adequate virus-receptor interactions and fusion of viral and cellular membranes. These results provide new insights about how anti-HIV cytotoxic T lymphocytes can be activated and are useful for anti-HIV vaccine design.

公开(公告)号：EP0730657B1

公开(公告)日：2008-04-30

申请号：EP95902161.9

申请日：1994-11-22

申请人： Aventis Pharma S.A. ,  INSTITUT PASTEUR ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

发明人： BEUZARD, Yves ,  DANOS, Olivier ,  DESCAMPS, Vincent ,  HEARD, Jean-Michel ,  MOULLIER, Philippe ,  NAFFAKH, Nadia ,  PERRICAUDET, Michel ,  VAINCHENKER, William

IPC分类号： C12N15/86 ,  C12N5/10 ,  A61K48/00

CPC分类号： A61K38/1816 ,  A61K48/00 ,  C07K14/505

摘要： The present invention provides cell compositions for in vivo implantation, and designed for the sustained and controlled delivery of therapeutic substances.

公开(公告)号：EP0702723B1

公开(公告)日：2002-09-04

申请号：EP94914431.5

申请日：1994-04-21

申请人： INSTITUT PASTEUR

发明人： MOULLIER, Philippe ,  DANOS, Olivier ,  HEARD, Jean-Michel ,  FERRY, Nicolas

IPC分类号： C12N15/86 ,  A61K48/00 ,  C12N5/10 ,  A61L27/00 ,  A61K9/14 ,  C12N9/24 ,  C12N15/27 ,  C12N9/12 ,  C12N15/12 ,  C12N15/56 ,  C12N15/54

CPC分类号： A61K9/0024 ,  A61K35/12 ,  A61K38/00 ,  A61K48/00 ,  A61L27/3604 ,  A61L27/3608 ,  A61L27/3683 ,  A61L27/38 ,  A61L27/3804 ,  A61L27/3839 ,  A61L27/3895 ,  C07K14/505 ,  C07K14/721 ,  C12N5/0068 ,  C12N9/10 ,  C12N9/1051 ,  C12N9/2402 ,  C12N15/86 ,  C12N2510/02 ,  C12N2533/18 ,  C12N2533/30 ,  C12N2533/54 ,  C12N2740/13043 ,  C12N2740/16043 ,  C12Y204/01017 ,  C12Y302/01031 ,  C12Y302/01076

摘要： The invention relates to an implant obtained by assembling in vitro various elements in order to form a neo-organ which is introduced preferably in the peritoneal cavity of the recipient. The implant comprises a biocompatible support intended to the biological anchoring of cells; cells having the capacity of expressing and secreting naturally or after recombination a predetermined compound, for example a compound having a therapeutical interest; and a constituent capable of inducing and/or promoting the geling of said cells. The invention also relates to a kit for the preparation of the implant as well as to a new recombinant retroviral vector comprising a provirus DNA sequence modified in that the genes gag, pol and env have been deleted at least partially so as to obtain a proviral DNA capable of replication. The invention also relates to recombinant cells comprising the new retroviral vector.